Platycodin D sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the PI3K/Akt signaling pathway
Cetuximab is a monoclonal antibody against epidermal growth factor receptor that blocks downstream signaling pathways of receptor tyrosine kinases, including Ras/Raf/MAPK and PI3K/Akt, thereby inhibiting tumor cell proliferation and inducing cancer cell apoptosis. Owing to KRAS mutations, the effect...
Main Authors: | Yanfei Liu, Shifeng Tian, Ben Yi, Zhiqiang Feng, Tianhao Chu, Jun Liu, Chunze Zhang, Shiwu Zhang, Yijia Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1046143/full |
Similar Items
-
Combined Anti-Cancer Effects of Platycodin D and Sorafenib on Androgen-Independent and PTEN-Deficient Prostate Cancer
by: Zongliang Lu, et al.
Published: (2021-05-01) -
Resveratrol Sensitizes Colorectal Cancer Cells to Cetuximab by Connexin 43 Upregulation-Induced Akt Inhibition
by: Yijia Wang, et al.
Published: (2020-04-01) -
Effects of Platycodin D on Proliferation, Apoptosis and PI3K/Akt Signal Pathway of Human Glioma U251 Cells
by: Chong Xu, et al.
Published: (2014-12-01) -
Unveiling the anticancer potential of platycodin D
by: Tae Kyung Hyun
Published: (2024-10-01) -
Exosomes promote cetuximab resistance via the PTEN/Akt pathway in colon cancer cells
by: S. Zhang, et al.
Published: (2017-11-01)